leisure time -WSS

leisure time

author：focus 2025-08-12 06:42:09 - browse：9718

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： AI models in health care face new federal disclosure requirements

entertainment

WSS

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

CRISPR gene editing developments we’re watching in 2024

Patients' immediate access to test results puts radiologists in a bind

Roche to buy Carmot Therapeutics, developer of obesity drugs

In Spain, a hospital brews its own CAR

Why sickle cell disease is getting the first CRISPR treatment

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medicare drug price negotiation hasn't dried up venture capital

Hepatitis C has a cure — but many Americans still lack access to it

AI models in health care face new federal disclosure requirements

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Three trends to watch in biotech in 2024

Hepatitis C has a cure — but many Americans still lack access to it

Bristol Myers buys into radiopharmaceuticals with RayzeBio

DIEP, the 'gold standard' of breast reconstruction, is under threat

Can sheer will power keep patients alive in their dying hours?

knowledge

Teach medical students about patients with intellectual disabilities

Prime Medicine, Myeloid Therapeutics clash over genome

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Pharma patents targeted by Biden in move to slash drug prices

Christmas in the PICU brings some surprising joy

Keeping primary care docs in field isn't impossible, says AAFP CEO

entertainment

focus

entertainment

hotspot